Risk factors
Axogen (AXGN) risk factors
Item 1A of every Axogen, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors60 risks9 new7 dropped18 reworded
Axogen secured FDA BLA approval for its Avance nerve graft product in December 2025, shifting risks to post-approval compliance and clinical study requirements. Accumulated deficit grew to $307.0 million with 2025 net losses of $15.7 million. New CMS payment categories created new reimbursement opportunities.
Filed Feb 24, 2026 - FY2024 10-K risk factors58 risks
Axogen relies heavily on Avance Nerve Graft, representing 60% of total revenue and awaiting FDA BLA approval.
Filed Feb 26, 2025